We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Eiger Biopharmaceuticals Inc
9 own
14 watching
Current Price
$0.32
$0
(-0.03%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
14.36M
52-Week High
3.96000
52-Week Low
0.21000
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
--
Market Capitalization14.36M52-Week High3.9600052-Week Low0.21000Average Volume0.21MDividend Yield--P/E Ratio--What does the Eiger Biopharmaceuticals Inc do?
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Read More
How much money does Eiger Biopharmaceuticals Inc make?
News & Events about Eiger Biopharmaceuticals Inc.
Ticker Report
7 months ago
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR Get Rating) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 2,710,000 shares, an increase of 9.3% from the March 31st total of 2,480,000 shares. Based on an average daily ...
Zolmax
7 months ago
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR Get Rating) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,710,000 shares, an increase of 9.3% from the March 31st total of 2,480,000 shares. Based on an average daily volume of ...
PR Newswire
7 months ago
Thinking about buying stock in Bit Digital, Cipher Mining, Eiger Biopharmaceuticals, Eos Energy, or Bitfarms? Thinking about buying stock in Bit Digital, Cipher Mining, Eiger Biopharmaceuticals, Eos Energy, or Bitfarms? PR Newswire NEW YORK, April 13, 2023 NEW YORK, April 13, 2023 /PRNewswire...
Globe Newswire
9 months ago
PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Eiger BioPharmaceuticals, Inc. (Eiger or the Company) (NASDAQ: EIGR) on behalf of the Companys long-term stockholders. Recently a shareholder class action complaint was ...
PR Newswire
11 months ago
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm PR Newswire LOS...
Frequently Asked Questions
Frequently Asked Questions
What is Eiger Biopharmaceuticals Inc share price today?
Can Indians buy Eiger Biopharmaceuticals Inc shares?
How can I buy Eiger Biopharmaceuticals Inc shares from India?
Can Fractional shares of Eiger Biopharmaceuticals Inc be purchased?
What are the documents required to start investing in Eiger Biopharmaceuticals Inc stocks?
What is today’s traded volume of Eiger Biopharmaceuticals Inc?
What is today’s market capitalisation of Eiger Biopharmaceuticals Inc?
What is the 52-Week High and Low Range of Eiger Biopharmaceuticals Inc?
What percentage is Eiger Biopharmaceuticals Inc down from its 52-Week High?
What percentage is Eiger Biopharmaceuticals Inc up from its 52-Week Low?
Current Price
$0.32
$0
(-0.03%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.